881

500124

DRREDDY

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

DR. REDDY S LABORATORIES Share Price Today

DR. REDDY S LABORATORIES is currently trading at ₹1277.7, up by ₹6.0 from the previous close. The stock touched an intraday high of ₹1285.70 and a low of ₹1266.40 during the latest trading session. Over the past one year, DR. REDDY S LABORATORIES has delivered a loss of 5.71%, while the stock has declined 0.64% in the last one month.

DR. REDDY S LABORATORIES performance

Today’s low Today’s high
₹ 1266.40 ₹ 1285.70
₹ 1275.10
52 week low 52 week high
₹ 1148.40 ₹ 1379.70
₹ 1275.10
Open Price ₹ 1271.10
Prev. Close ₹ 1271.70
Volume (Shares) 751222.00
Total traded value ₹ 9578.83
Upper Circuit ₹ 1398.80
Lower Circuit ₹ 1144.60
info

Investment Returns

Over 1 Month -0.64% Over 3 Months -3.26% Over 6 Months 1.67% Over 1 Year -5.71%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

DR. REDDY S LABORATORIES fundamentals


  • Market cap (Cr) 1,06,478.70
  • P/E Ratio (TTM) 32.97
  • Beta 0.55
  • Book Value / share 375.78
  • Return on equity 20.15%
  • EPS (TTM) 38.57
  • Dividend yield 0.63%
  • Net profit/quarter (Cr) -219.40
info icon alternate text
  • Market cap (Cr) 1,06,253.40
  • P/E Ratio (TTM) 32.97
  • Beta 0.50
  • Book Value / share 375.78
  • Return on equity 20.15%
  • EPS (TTM) 38.57
  • Dividend yield 0.63%
  • Net profit/quarter (Cr) -219.40
info icon alternate text

DR. REDDY S LABORATORIES Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 3802.60
Operating Expense 4694.70
Net Profit -219.40
Net Profit Margin (%) -5.76
Earnings Per Share (EPS) -2.63
EBITDA 67.30
Effective Tax Rate (%) 28.18
Particulars DEC 2025 (Values in Cr)
Revenue 4266.40
Operating Expense 4538.79
Net Profit 90.60
Net Profit Margin (%) 2.12
Earnings Per Share (EPS) 1.09
EBITDA 459.90
Effective Tax Rate (%) 13.05
Particulars SEP 2025 (Values in Cr)
Revenue 4602.90
Operating Expense 4466.50
Net Profit 387.30
Net Profit Margin (%) 8.41
Earnings Per Share (EPS) 4.65
EBITDA 844.50
Effective Tax Rate (%) 24.98
Particulars JUN 2025 (Values in Cr)
Revenue 7788.70
Operating Expense 4271.50
Net Profit 2961.20
Net Profit Margin (%) 38.01
Earnings Per Share (EPS) 35.59
EBITDA 4235.30
Effective Tax Rate (%) 24.77
Particulars MAR 2025 (Values in Cr)
Revenue 5546.30
Operating Expense 4415.50
Net Profit 1200.70
Net Profit Margin (%) 21.64
Earnings Per Share (EPS) 14.41
EBITDA 1857.39
Effective Tax Rate (%) 23.12
Particulars MAR 2026 (Values in Cr)
Revenue 20460.60
Operating Expense 17971.10
Net Profit 3219.70
Net Profit Margin (%) 15.73
Earnings Per Share (EPS) 38.68
EBITDA 5607.00
Effective Tax Rate (%) 24.26
Particulars MAR 2025 (Values in Cr)
Revenue 23046.80
Operating Expense 16882.90
Net Profit 5349.40
Net Profit Margin (%) 23.21
Earnings Per Share (EPS) 64.22
EBITDA 8385.19
Effective Tax Rate (%) 26.07
Particulars MAR 2024 (Values in Cr)
Revenue 19404.10
Operating Expense 14554.80
Net Profit 4342.00
Net Profit Margin (%) 22.37
Earnings Per Share (EPS) 260.95
EBITDA 6788.70
Effective Tax Rate (%) 25.02
Particulars MAR 2023 (Values in Cr)
Revenue 16899.10
Operating Expense 13687.80
Net Profit 2612.80
Net Profit Margin (%) 15.46
Earnings Per Share (EPS) 157.37
EBITDA 4806.10
Effective Tax Rate (%) 32.41
Particulars MAR 2022 (Values in Cr)
Revenue 14315.30
Operating Expense 12663.40
Net Profit 1623.20
Net Profit Margin (%) 11.33
Earnings Per Share (EPS) 97.85
EBITDA 3076.10
Effective Tax Rate (%) 27.00
Particulars MAR 2025 (Values in Cr)
Book Value / Share 402.27
ROE % 18.53
ROCE % 23.05
Total Debt to Total Equity 0.11
EBITDA Margin 29.61
Particulars MAR 2024 (Values in Cr)
Book Value / Share 1693.93
ROE % 21.64
ROCE % 26.59
Total Debt to Total Equity 0.06
EBITDA Margin 31.57
Particulars MAR 2023 (Values in Cr)
Book Value / Share 1405.34
ROE % 21.21
ROCE % 25.99
Total Debt to Total Equity 0.11
EBITDA Margin 30.16
Particulars MAR 2022 (Values in Cr)
Book Value / Share 1164.21
ROE % 11.84
ROCE % 14.46
Total Debt to Total Equity 0.17
EBITDA Margin 20.06
Particulars MAR 2021 (Values in Cr)
Book Value / Share 1072.02
ROE % 11.74
ROCE % 15.29
Total Debt to Total Equity 0.16
EBITDA Margin 22.10
Particulars MAR 2025 (Values in Cr)
Book Value / Share 346.00
ROE % 20.15
ROCE % 25.47
Total Debt to Total Equity 0.08
EBITDA Margin 36.28
Particulars MAR 2024 (Values in Cr)
Book Value / Share 1453.29
ROE % 19.42
ROCE % 25.40
Total Debt to Total Equity 0.02
EBITDA Margin 34.84
Particulars MAR 2023 (Values in Cr)
Book Value / Share 1236.56
ROE % 13.46
ROCE % 18.82
Total Debt to Total Equity 0.06
EBITDA Margin 28.33
Particulars MAR 2022 (Values in Cr)
Book Value / Share 1111.56
ROE % 9.19
ROCE % 11.63
Total Debt to Total Equity 0.10
EBITDA Margin 21.35
Particulars MAR 2021 (Values in Cr)
Book Value / Share 1032.48
ROE % 11.50
ROCE % 15.04
Total Debt to Total Equity 0.08
EBITDA Margin 25.97
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 2460.20
Total Assets 49426.60
Total Liabilities 49426.60
Total Equity 33927.40
Share Outstanding 83
Price to Book Ratio 3.31
Return on Assets (%) 11.44
Return on Capital (%) 14.84
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1727.70
Total Assets 38863.80
Total Liabilities 38863.80
Total Equity 28254.80
Share Outstanding 16
Price to Book Ratio 4.24
Return on Assets (%) 14.35
Return on Capital (%) 18.65
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1730.20
Total Assets 32285.10
Total Liabilities 32285.10
Total Equity 23286.10
Share Outstanding 16
Price to Book Ratio 3.74
Return on Assets (%) 13.96
Return on Capital (%) 18.47
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2419.20
Total Assets 29746.90
Total Liabilities 29746.90
Total Equity 19212.40
Share Outstanding 16
Price to Book Ratio 3.87
Return on Assets (%) 7.33
Return on Capital (%) 9.79
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2078.80
Total Assets 26616.80
Total Liabilities 26616.80
Total Equity 17641.70
Share Outstanding 16
Price to Book Ratio 4.37
Return on Assets (%) 7.33
Return on Capital (%) 9.6
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 976.80
Total Assets 38290.90
Total Liabilities 38290.90
Total Equity 28856.60
Share Outstanding 83
Price to Book Ratio 3.31
Return on Assets (%) 13.97
Return on Capital (%) 16.59
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1216.90
Total Assets 30359.30
Total Liabilities 30359.30
Total Equity 24240.80
Share Outstanding 16
Price to Book Ratio 4.24
Return on Assets (%) 14.30
Return on Capital (%) 17.4
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 645.80
Total Assets 25374.80
Total Liabilities 25374.80
Total Equity 20474.20
Share Outstanding 16
Price to Book Ratio 3.74
Return on Assets (%) 10.29
Return on Capital (%) 12.76
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2030.50
Total Assets 24495.60
Total Liabilities 24495.60
Total Equity 18336.20
Share Outstanding 16
Price to Book Ratio 3.87
Return on Assets (%) 6.62
Return on Capital (%) 7.92
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1646.50
Total Assets 21629.60
Total Liabilities 21629.60
Total Equity 16983.70
Share Outstanding 16
Price to Book Ratio 4.37
Return on Assets (%) 10.10
Return on Capital (%) 12.04
Particulars MAR 2025 (Values in Cr)
Net Income 7679.50
Cash from Operations 6642.10
Cash from Investing -5807.70
Cash from Financing 1891.10
Net change in Cash 726.20
Free Cash Flow 9392.50
Particulars MAR 2024 (Values in Cr)
Net Income 7201.00
Cash from Operations 6548.00
Cash from Investing -4028.30
Cash from Financing -376.30
Net change in Cash 138.70
Free Cash Flow 8188.30
Particulars MAR 2023 (Values in Cr)
Net Income 6048.50
Cash from Operations 6958.90
Cash from Investing -4137.30
Cash from Financing -2686.10
Net change in Cash -935.90
Free Cash Flow 8091.20
Particulars MAR 2022 (Values in Cr)
Net Income 3061.40
Cash from Operations 3554.50
Cash from Investing -2638.70
Cash from Financing -242.20
Net change in Cash -70.10
Free Cash Flow 5020.50
Particulars MAR 2021 (Values in Cr)
Net Income 2883.50
Cash from Operations 4141.90
Cash from Investing -2266.00
Cash from Financing -29.80
Net change in Cash 1274.50
Free Cash Flow 5116.00
Particulars MAR 2025 (Values in Cr)
Net Income 7235.90
Cash from Operations 5811.40
Cash from Investing -5697.60
Cash from Financing 1590.70
Net change in Cash 118.10
Free Cash Flow 8150.70
Particulars MAR 2024 (Values in Cr)
Net Income 5791.30
Cash from Operations 4769.20
Cash from Investing -3430.30
Cash from Financing 68.10
Net change in Cash 87.50
Free Cash Flow 6130.29
Particulars MAR 2023 (Values in Cr)
Net Income 3866.00
Cash from Operations 5835.60
Cash from Investing -3447.60
Cash from Financing -2696.90
Net change in Cash -1091.60
Free Cash Flow 6835.80
Particulars MAR 2022 (Values in Cr)
Net Income 2223.80
Cash from Operations 1827.50
Cash from Investing -2038.00
Cash from Financing 505.50
Net change in Cash -193.80
Free Cash Flow 3138.80
Particulars MAR 2021 (Values in Cr)
Net Income 3056.20
Cash from Operations 3962.20
Cash from Investing -1458.00
Cash from Financing -794.30
Net change in Cash 1261.90
Free Cash Flow 4819.70
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENTERPRISES L 33.07 13.67 1.60 253.43 23.12 38.85
BLISS GVS PHARMA LTD 423.70 34.28 3.75 4482.28 118.35 462.70
CIPLA LTD. 1376.25 29.21 3.22 111179.71 1165.55 1672.20
FERMENTA BIOTECH LTD. 327.50 14.45 2.37 963.86 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENTERPRISES L 33.07 23.13 4.26 253.43 23.12 38.85
AMRUTANJAN HEALTH CARE LTD. 568.05 25.46 4.43 1642.27 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8304.35 108.45 23.78 20760.88 7630.00 10653.05
BLISS GVS PHARMA LTD 423.70 45.56 3.88 4482.28 118.35 462.70

DR. REDDY S LABORATORIES shareholding pattern

Holding
9.56%
26.63%
33.08%
30.71%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

DR. REDDY S LABORATORIES Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1275.70 0.31 redarrow
red-green-graph indicator
11 Bearish
5 Bullish
  • 5 Days 1273.80
  • 26 Days 1289.10
  • 10 Days 1281.20
  • 50 Days 1285.20
  • 12 Days 1283.60
  • 100 Days 1275.70
  • 20 Days 1288.50
  • 200 Days 1268.20
1274.03 PIVOT
First Support 1264.37 First Resistance 1281.37 Second Support 1257.03 Second Resistance 1291.03 Third Support 1247.37 Third Resistance 1298.37
RSI 44.45 ADX 26.99 MACD -5.54 Williams % R -76.32 Commodity Channel Index (CCI) -72.47
Date 2026-06-10 Week 512885.00 Same Day 655147.00 Month 1289138.00
1 Year 0.56 3 Year 0.55
Over 1 Month
-0.64% down
Over 1 Year
-5.71% down
Over 3 Months
-3.26% down
Over 3 Years
10.79% down
Over 6 Months
1.67% down
Over 5 Years
3.73% down

DR. REDDY S LABORATORIES Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
10 Jul 2026 8.0 Final 10 Jul 2026 Equity shares
10 Jul 2025 8.0 Final 10 Jul 2025 Equity shares
16 Jul 2024 40.0 Final 17 Jul 2024 Equity shares
11 Jul 2023 40.0 Final 12 Jul 2023 Equity shares
11 Jul 2022 30.0 Final 13 Jul 2022 Equity shares
09 Jul 2021 25.0 Final 13 Jul 2021 Equity shares
13 Jul 2020 25.0 Final 15 Jul 2020 Equity shares
15 Jul 2019 20.0 Final 17 Jul 2019 Equity shares
16 Jul 2018 20.0 Final 18 Jul 2018 Equity shares
17 Jul 2017 20.0 Final 19 Jul 2017 Equity shares
18 Jul 2016 20.0 Final 20 Jul 2016 Equity shares
10 Jul 2015 20.0 Final 14 Jul 2015 Equity shares
11 Jul 2014 18.0 Final 15 Jul 2014 Equity shares
12 Jul 2013 15.0 Final 16 Jul 2013 Equity shares
28 Jun 2012 13.75 Final 03 Jul 2012 Equity shares
30 Jun 2011 11.25 Final 05 Jul 2011 Equity shares
02 Jul 2010 11.25 Final 06 Jul 2010 Equity shares
03 Jul 2009 6.25 Final 07 Jul 2009 Equity shares
04 Jul 2008 3.75 Final 08 Jul 2008 Equity shares
06 Jul 2007 3.75 Final 10 Jul 2007 Equity shares
07 Jul 2006 0.0 Final 11 Jul 2006 Equity shares
07 Jul 2005 0.0 Final 11 Jul 2005 Equity shares
Ex-Date Ex-Bonus Ratio
29 Aug 2006 28 Aug 2006 1:1
03 May 1994 08 Apr 1994 2:1
Ex-Date Old FV NEW FV Record Date
28 Oct 2024 5.0 1.0 28 Oct 2024
10 Oct 2001 10.0 5.0 25 Oct 2001
Dividend date Dividend amount Dividend type Record date Instrument type
10 Jul 2026 8.0 Final 10 Jul 2026 Equity shares
10 Jul 2025 8.0 Final 10 Jul 2025 Equity shares
16 Jul 2024 40.0 Final 17 Jul 2024 Equity shares
11 Jul 2023 40.0 Final 12 Jul 2023 Equity shares
11 Jul 2022 30.0 Final 13 Jul 2022 Equity shares
09 Jul 2021 25.0 Final 13 Jul 2021 Equity shares
13 Jul 2020 25.0 Final 15 Jul 2020 Equity shares
15 Jul 2019 20.0 Final 17 Jul 2019 Equity shares
16 Jul 2018 20.0 Final 18 Jul 2018 Equity shares
17 Jul 2017 20.0 Final 19 Jul 2017 Equity shares
18 Jul 2016 20.0 Final 20 Jul 2016 Equity shares
10 Jul 2015 20.0 Final 14 Jul 2015 Equity shares
11 Jul 2014 18.0 Final 15 Jul 2014 Equity shares
12 Jul 2013 15.0 Final 16 Jul 2013 Equity shares
28 Jun 2012 13.75 Final 03 Jul 2012 Equity shares
30 Jun 2011 11.25 Final 05 Jul 2011 Equity shares
02 Jul 2010 11.25 Final 06 Jul 2010 Equity shares
03 Jul 2009 6.25 Final 07 Jul 2009 Equity shares
04 Jul 2008 3.75 Final 08 Jul 2008 Equity shares
06 Jul 2007 3.75 Final 10 Jul 2007 Equity shares
07 Jul 2006 0.0 Final 11 Jul 2006 Equity shares
07 Jul 2005 0.0 Final 11 Jul 2005 Equity shares
Ex-Date Ex-Bonus Ratio
29 Aug 2006 28 Aug 2006 1:1
03 May 1994 08 Apr 1994 2:1
Ex-Date Old FV NEW FV Record Date
28 Oct 2024 5.0 1.0 28 Oct 2024
10 Oct 2001 10.0 5.0 25 Oct 2001

Top Gainers

Top Losers

Dr. Reddy's Laboratories share result highlights

Dr. Reddy’s Laboratories posted consolidated sales of ₹8,572 crore in Q1 FY25-26 versus ₹7,696 crore in Q1 FY24-25. Expenses stood at ₹6,398 crore in Q1 FY25-26 against ₹5,566 crore in Q1 FY24-25. Operating profit was ₹2,174 crore in Q1 FY25-26 compared with ₹2,130 crore in Q1 FY24-25. Net profit was recorded at ₹1,410 crore in Q1 FY25-26 versus ₹1,392 crore in Q1 FY24-25.

Date Source: screener.in, and corporate filings on NSE/BSE

Dr. Reddy's Laboratories share annual reports

Dr. Reddy’s Laboratories reported consolidated sales of ₹32,644 crore in FY24-25 versus ₹28,011 crore in FY23-24. Expenses stood at ₹24,097 crore in FY24-25 against ₹20,078 crore in FY23-24. Operating profit was ₹8,547 crore in FY24-25 compared with ₹7,933 crore in FY23-24. Net profit was recorded at ₹5,725 crore in FY24-25 versus ₹5,578 crore in FY23-24.

Date Source: screener.in, and corporate filings on NSE/BSE

Dr. Reddy's Laboratories share dividend

Dr. Reddy’s Laboratories paid a dividend of ₹8 per share with ex-date of 10 Jul 2025. In the previous year, the company paid ₹40 per share on 16 Jul 2024. Earlier, it paid ₹40 per share on 11 Jul 2023, ₹30 per share on 11 Jul 2022, ₹25 per share on 9 Jul 2021, ₹25 per share on 13 Jul 2020, and ₹20 per share on 15 Jul 2019.

Date Source: screener.in, and corporate filings on NSE/BSE

stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Dr Reddys Laboratories Ltd?

Answer Field

Dr Reddys Laboratories Ltd share price is for NSE ₹ 1,277.70 & for BSE ₹ 1,275.05 as on Jun 11 2026 03:29 PM.

What is the Market Cap of Dr Reddys Laboratories Ltd Share?

Answer Field

The market cap of Dr Reddys Laboratories Ltd for NSE ₹ 0.01 & for BSE ₹ 0.01 as on Jun 11 2026 03:29 PM.

What is the 52 Week High and Low of Dr Reddys Laboratories Ltd?

Answer Field

The 52 Week High and Low of Dr Reddys Laboratories Ltd for NSE is ₹ 1,379.70 and ₹ 1,148.40 and for BSE is ₹ 1,377.95 and ₹ 1,149.00.

What is 1 year return for Dr Reddys Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been -5.71%.

What is the P/E Ratio of Dr Reddys Laboratories Ltd Share?

Answer Field

As on Jun 11 2026 03:29 PM the price-to-earnings (PE) ratio for Dr Reddys Laboratories Ltd share is 32.97.

What is the PB ratio of Dr Reddys Laboratories Ltd Share?

Answer Field

As on Jun 11 2026 03:29 PM, the price-to-book (PB) ratio for Dr Reddys Laboratories Ltd share is 375.78.

How to Buy Dr Reddys Laboratories Ltd Share?

Answer Field

You can trade in Dr Reddys Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Dr Reddys Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Dr Reddys Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Dr Reddys Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

Who is the CEO of Dr Reddy's Laboratories Ltd?

Answer Field

Erez Israeli has held the position of CEO at Dr Reddy's Laboratories Ltd since 1 Aug 2019. He leads the company in advancing pharmaceutical innovations and global market reach, focusing on sustainable growth and maintaining Dr Reddy's competitive position within the industry.

When was Dr Reddy's Laboratories Ltd established?

Answer Field

Dr Reddy's Laboratories Ltd was founded in 1984 in Hyderabad, India, by Dr. Anji Reddy. The company began by manufacturing Active Pharmaceutical Ingredients (APIs) and quickly expanded to become one of India’s leading pharmaceutical companies with a significant global presence.

What factors influence the Dr Reddy Share Price?

Answer Field

Dr Reddy share price is influenced by multiple factors, including financial performance, revenue growth, and profitability. Sector trends, global market conditions, regulatory changes, and investor sentiment also impact share value, shaping the overall market perception of Dr Reddy's potential for future growth.

Is Dr Reddy's Laboratories Ltd debt free?

Answer Field

Dr Reddy's Laboratories Ltd is not entirely debt-free; however, the company maintains a balanced debt-to-equity ratio, ensuring debt levels remain manageable. This strategic financial management allows Dr Reddy's to invest in growth opportunities while maintaining financial stability and supporting long-term shareholder value.

What is the CAGR of Dr Reddy Share?

Answer Field

The Compound Annual Growth Rate (CAGR) for Dr Reddy share is 6% over 10 years, 19% over 5 years, 10% over 3 years, and 19% over the last year. These figures reflect the company’s growth trajectory and its consistent performance in the pharmaceutical sector.

How has the Dr Reddy Share Price performed over the past year?

Answer Field

Over the past year, Dr Reddy share price has demonstrated a positive performance, showing a 19% growth in CAGR. This growth highlights investor confidence and reflects the company’s strong market position, profitability, and financial resilience within the highly competitive pharmaceutical industry.

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|